CSL Stock Price, News & Analysis (ASX:CSL)

A$142.16 -0.84 (-0.59 %)
(As of 01/16/2018 08:27 AM ET)
Previous CloseA$143.00
Today's RangeA$142.08 - A$143.14
52-Week RangeA$98.94 - A$149.30
Volume399,701 shs
Average Volume713,558 shs
Market Capitalization$64.63 billion
P/E Ratio38.32
Dividend Yield1.03%
BetaN/A

About CSL (ASX:CSL)

CSL logoCSL Limited is a biotherapeutics company that develops and delivers biotherapies. The Company's principal activities are research, development, manufacture, marketing and distribution of biopharmaceutical and allied products. Its segments include CSL Behring, Seqirus and CSL Intellectual Property. The CSL Behring segment manufactures, markets and develops plasma therapies (plasma products and recombinants). The Seqirus segment manufactures and distributes non-plasma biotherapeutic products. Seqirus manufactures, sells and distributes a range of vaccines, antivenoms and other pharmaceutical products in Australia and New Zealand. It also manufactures and markets in vitro diagnostic products through Seqirus immunohematology. The CSL Intellectual Property segment is engaged in licensing of intellectual property generated by the Company to unrelated third parties. The Company has facilities in Australia, Germany, Switzerland, the United Kingdom and the United States.

Receive CSL News and Ratings via Email

Sign-up to receive the latest news and ratings for CSL and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorHealthcare
SymbolASX:CSL
CUSIPN/A
Phone+61-3-93891911

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E Ratio38.3180592991914
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPSA$3.71
Net IncomeN/A
Net Margins16.35%
Return on Equity34.95%
Return on Assets12.30%

Miscellaneous

EmployeesN/A
Outstanding Shares453,250,000

CSL (ASX:CSL) Frequently Asked Questions

What is CSL's stock symbol?

CSL trades on the ASX under the ticker symbol "CSL."

Who are some of CSL's key competitors?

Who are CSL's key executives?

CSL's management team includes the folowing people:

  • Paul Perreault, Chief Executive Officer, Managing Director, Executive Director (Age 60)
  • David Mark Lamont, Chief Financial Officer (Age 52)
  • Gordon Naylor, President - Seqirus (Age 54)
  • Greg Boss, Executive Vice President, Legal and CSL Group General Counsel (Age 56)
  • Karen Etchberger, Executive Vice President - Quality and Business Services (Age 59)
  • Bob Repella, Executive Vice President - Global Commercial Operations (Age 58)
  • Val Romberg, Executive Vice President of Manufacturing and Planning (Age 59)
  • Alan J. Wills, Senior Vice President - Strategy and Business Development (Age 53)
  • Andrew Cuthbertson, Chief Scientific Officer, R&D Director (Age 62)
  • Laurie Reed, Senior Vice President - Human Resources (Age 53)

What is CSL's stock price today?

One share of CSL stock can currently be purchased for approximately A$142.16.

How big of a company is CSL?

CSL has a market capitalization of $64.63 billion.

How can I contact CSL?

CSL's mailing address is 45 Poplar Rd, MELBOURNE, VIC 3052, Australia. The company can be reached via phone at +61-3-93891911.


MarketBeat Community Rating for CSL (CSL)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  124 (Vote Outperform)
Underperform Votes:  78 (Vote Underperform)
Total Votes:  202
MarketBeat's community ratings are surveys of what our community members think about CSL and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

CSL (ASX:CSL) Analyst Ratings History


No equities research coverage for this company has been tracked by MarketBeat

Earnings

Earnings History for CSL (ASX:CSL)


No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

CSL (ASX:CSL) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for CSL (ASX:CSL)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for CSL (ASX CSL)

No insider trades for this company have been tracked by MarketBeat.com

Headlines

CSL (ASX CSL) News Headlines

Source:
DateHeadline
Is CSL Limited’s (ASX:CSL) Balance Sheet Strong Enough To Weather A Storm?Is CSL Limited’s (ASX:CSL) Balance Sheet Strong Enough To Weather A Storm?
finance.yahoo.com - January 9 at 10:02 AM
Australia shares extend gains on materials; NZ falls from record highAustralia shares extend gains on materials; NZ falls from record high
www.reuters.com - December 20 at 10:09 AM
10 top shares for 201810 top shares for 2018
www.fool.com.au - December 20 at 10:09 AM
UPDATE 1-Dangote Cement shares trade in $350 mln off-market deal -tradersUPDATE 1-Dangote Cement shares trade in $350 mln off-market deal -traders
www.reuters.com - December 18 at 4:46 PM
ETFs with exposure to CSL Ltd. : December 15, 2017ETFs with exposure to CSL Ltd. : December 15, 2017
finance.yahoo.com - December 15 at 5:07 PM
CSL Ltd. – Value Analysis (ASX:CSL) : December 14, 2017CSL Ltd. – Value Analysis (ASX:CSL) : December 14, 2017
finance.yahoo.com - December 14 at 5:20 PM
CSL Ltd. breached its 50 day moving average in a Bearish Manner : CSL-AU : December 13, 2017CSL Ltd. breached its 50 day moving average in a Bearish Manner : CSL-AU : December 13, 2017
finance.yahoo.com - December 13 at 10:26 AM
Australia shares flat ahead of Fed rate decision, NZ upAustralia shares flat ahead of Fed rate decision, NZ up
www.reuters.com - December 11 at 10:49 AM
December Top Growth StocksDecember Top Growth Stocks
finance.yahoo.com - December 10 at 9:59 AM
Should You Sell CSL Limited (ASX:CSL) At This PE Ratio?Should You Sell CSL Limited (ASX:CSL) At This PE Ratio?
finance.yahoo.com - December 8 at 10:04 AM
Myasthenia Gravis Market Value to Reach US$2,313.1 Million by the End of 2025: Transparency Market ResearchMyasthenia Gravis Market Value to Reach US$2,313.1 Million by the End of 2025: Transparency Market Research
finance.yahoo.com - December 5 at 11:49 AM
Top broker thinks CSL Limited shares are worth $155Top broker thinks CSL Limited shares are worth $155
www.fool.com.au - December 5 at 11:49 AM
CSL and Vitaeris Announce Strategic Partnership with Option to AcquireCSL and Vitaeris Announce Strategic Partnership with Option to Acquire
finance.yahoo.com - December 5 at 11:49 AM
CSL Behring Advances to Phase 3 Cardiovascular Outcomes Trial for CSL112, its Novel Apolipoprotein A-I (Human) Infusion TherapyCSL Behring Advances to Phase 3 Cardiovascular Outcomes Trial for CSL112, its Novel Apolipoprotein A-I (Human) Infusion Therapy
finance.yahoo.com - December 4 at 4:48 PM
Be FLUent Partnership Shines Spotlight on Importance of Flu Prevention in Seniors - PR Newswire (press release)Be FLUent Partnership Shines Spotlight on Importance of Flu Prevention in Seniors - PR Newswire (press release)
www.prnewswire.com - December 4 at 10:05 AM
Be FLUent Partnership Shines Spotlight on Importance of Flu Prevention in SeniorsBe FLUent Partnership Shines Spotlight on Importance of Flu Prevention in Seniors
finance.yahoo.com - December 4 at 10:05 AM
Australia shares headed for 4th week of gains in 5; NZ inches upAustralia shares headed for 4th week of gains in 5; NZ inches up
www.reuters.com - December 2 at 4:41 PM
Macquarie Group Ltd thinks these expensive shares offer the best ... - Motley Fool AustraliaMacquarie Group Ltd thinks these expensive shares offer the best ... - Motley Fool Australia
www.fool.com.au - November 29 at 10:11 AM
Aussie shares muted on bearish message from China; NZ upAussie shares muted on bearish message from China; NZ up
www.reuters.com - November 24 at 11:01 AM
Australian shares tick up on materials, oil; NZ flatAustralian shares tick up on materials, oil; NZ flat
www.reuters.com - November 21 at 10:43 PM
Financials drag down Australian shares, NZ upFinancials drag down Australian shares, NZ up
www.reuters.com - November 20 at 6:35 PM
Aussie shares rise, but have worst week since June; NZ upAussie shares rise, but have worst week since June; NZ up
www.reuters.com - November 17 at 6:49 PM
2 exciting biotech shares to watch in 20182 exciting biotech shares to watch in 2018
www.fool.com.au - November 8 at 10:48 PM
Why shares of Mayne Pharma Group Ltd are bouncing off 52-week lows - Motley Fool AustraliaWhy shares of Mayne Pharma Group Ltd are bouncing off 52-week lows - Motley Fool Australia
www.fool.com.au - November 7 at 6:02 AM
Why CSL Limited shares are your best bet on Melbourne Cup Day - Motley Fool AustraliaWhy CSL Limited shares are your best bet on Melbourne Cup Day - Motley Fool Australia
www.fool.com.au - November 7 at 6:02 AM
How I would invest $50,000 in the ASXHow I would invest $50,000 in the ASX
www.fool.com.au - November 6 at 3:19 AM
CSL Limited shares are up 40% this year: Is it too late to invest?CSL Limited shares are up 40% this year: Is it too late to invest?
www.fool.com.au - October 31 at 6:48 PM
Data on the Preventive Effects of HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]) in Subjects with Very ... - PR Newswire (press release)Data on the Preventive Effects of HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]) in Subjects with Very ... - PR Newswire (press release)
www.prnewswire.com - October 30 at 9:27 PM
Data on the Preventive Effects of HAEGARDA® (C1 Esterase Inhibitor Subcutaneous ) in Subjects with Very Frequent HAE Attacks Presented by CSL Behring at the 2017 ACAAI Annual Scientific MeetingData on the Preventive Effects of HAEGARDA® (C1 Esterase Inhibitor Subcutaneous ) in Subjects with Very Frequent HAE Attacks Presented by CSL Behring at the 2017 ACAAI Annual Scientific Meeting
finance.yahoo.com - October 29 at 4:57 PM
New Data for HAEGARDA® (C1 Esterase Inhibitor Subcutaneous ) to be presented at the 2017 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific MeetingNew Data for HAEGARDA® (C1 Esterase Inhibitor Subcutaneous ) to be presented at the 2017 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting
finance.yahoo.com - October 24 at 7:58 PM
Why Sirtex Medical Limited shares are falling flat with its dose salesWhy Sirtex Medical Limited shares are falling flat with its dose sales
www.fool.com.au - October 23 at 11:08 PM
Is the CSL Limited CEO paid too much? - Motley Fool AustraliaIs the CSL Limited CEO paid too much? - Motley Fool Australia
www.fool.com.au - October 19 at 12:00 AM
CSL Chairman Says Majority Of Shareholders Agree To Support Remuneration ReportCSL Chairman Says Majority Of Shareholders Agree To Support Remuneration Report
www.rttnews.com - October 18 at 4:25 AM
Antithrombin Market to Attract a Revenue of US $704.5 Million by 2025 Globally: Transparency Market ResearchAntithrombin Market to Attract a Revenue of US $704.5 Million by 2025 Globally: Transparency Market Research
www.marketwatch.com - October 17 at 6:20 PM
Is the CSL Limited share price still in the buy zone? - Motley Fool AustraliaIs the CSL Limited share price still in the buy zone? - Motley Fool Australia
www.fool.com.au - October 12 at 6:20 PM
CSL Behring Trains Employees to Save Lives in Their Communities and Workplace with CPR; AHA Encourages Other Businesses to Do the SameCSL Behring Trains Employees to Save Lives in Their Communities and Workplace with CPR; AHA Encourages Other Businesses to Do the Same
finance.yahoo.com - October 12 at 6:20 PM
Will the Australian Dollar (A$) Fall by Christmas?Will the Australian Dollar (A$) Fall by Christmas?
www.fool.com.au - October 11 at 4:51 AM
Lessons learned from 3 stocks that would have made me richLessons learned from 3 stocks that would have made me rich
www.fool.com.au - October 9 at 9:01 PM
[$$] CSL hopes acquisition will fix blood supply problem in China[$$] CSL hopes acquisition will fix blood supply problem in China
finance.yahoo.com - October 8 at 4:43 PM
BRIEF-CSL closes new US$700 million private placement in U.S.BRIEF-CSL closes new US$700 million private placement in U.S.
www.reuters.com - October 6 at 10:53 PM
How safe is your money in Cochlear Limited shares? - Motley Fool AustraliaHow safe is your money in Cochlear Limited shares? - Motley Fool Australia
www.fool.com.au - October 5 at 4:46 PM
Intravenous Immunoglobulin [IVIg] Market to Grow Swiftly Owing to Rise in Number of Hemorrhage Sicknesses & CIDP Cases: Million InsightsIntravenous Immunoglobulin [IVIg] Market to Grow Swiftly Owing to Rise in Number of Hemorrhage Sicknesses & CIDP Cases: Million Insights
www.marketwatch.com - October 4 at 11:34 AM
Japans Ministry of Health, Labour and Welfare Approves AFSTYLA® - CSL Behrings Novel Recombinant Haemophilia A TreatmentJapan's Ministry of Health, Labour and Welfare Approves AFSTYLA® - CSL Behring's Novel Recombinant Haemophilia A Treatment
www.prnewswire.com - September 28 at 5:24 PM
Can the CSL Limited share price reach $200?Can the CSL Limited share price reach $200?
www.fool.com.au - September 28 at 12:09 AM
Why the Starpharma Holdings Limited share price rocketed higher ... - Motley Fool AustraliaWhy the Starpharma Holdings Limited share price rocketed higher ... - Motley Fool Australia
www.fool.com.au - September 22 at 9:40 PM
Is the CSL Limited share price about to storm higher?Is the CSL Limited share price about to storm higher?
www.fool.com.au - September 19 at 10:37 PM
CSL Behring Will Help Transform Biotech Education and Research with $4.92 Million Gift to Penn StateCSL Behring Will Help Transform Biotech Education and Research with $4.92 Million Gift to Penn State
finance.yahoo.com - September 19 at 5:35 PM
Seqirus Donates Influenza Vaccine for Hurricane Harvey Relief in Texas - Business Wire (press release)Seqirus Donates Influenza Vaccine for Hurricane Harvey Relief in Texas - Business Wire (press release)
www.businesswire.com - September 15 at 11:04 PM
CSL Behring Joins Together With Conference Attendees to Make Donation to IPOPI - PR Newswire (press release)CSL Behring Joins Together With Conference Attendees to Make Donation to IPOPI - PR Newswire (press release)
www.prnewswire.com - September 15 at 11:04 PM
CSL Behring Announces FDA Approval of Privigen® [Immune Globulin Intravenous (Human), 10% Liquid] for the ... - PR Newswire (press release)CSL Behring Announces FDA Approval of Privigen® [Immune Globulin Intravenous (Human), 10% Liquid] for the ... - PR Newswire (press release)
www.prnewswire.com - September 15 at 11:04 PM

SEC Filings

CSL (ASX:CSL) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Social activity is not available for this stock.

Financials

Financials are not available for this stock.

Chart

CSL (ASX CSL) Stock Chart for Tuesday, January, 16, 2018

Loading chart…

This page was last updated on 1/16/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.